The Federal Circuit’s Actavis ruling clarifies the tax treatment of ANDA patent litigation costs, providing for deductibility of litigation expenses for generic pharmaceutical companies
Read more hereThe information provided is not intended to be a comprehensive review of all developments in the law and practice, or to cover all aspects of those referred to.
Readers should take legal advice before applying it to specific issues or transactions.
Editorial Disclaimer
Originally published before the Ashurst Perkins Coie combination. See disclaimer.
